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Identity 
Other names: BP-1, 4EBP1, 4E-BP1, PHAS-I, 
MGC4316 




The EIF4EBP1 gene codes for 4E-BP1, one member of 
a family of small proteins that act as repressors of 
translation.  
The gene is 29,86 kb in length and contains three 
exons, comprising nucleotides 1-217, 218-397 and 398-
859 of the mature mRNA. 
Transcription 
EIF4EBP1 transcription is positively regulated by 
ATF4 in response to cell stress (Yamaguchi et al., 
2008) and by Smad4 in response to transforming 
growth factor β (Azar et al., 2009).  
There is evidence that activity of the 
phosphatidylinositol 3-kinase (PI3K) and MAP kinase 
pathways can negatively regulate the transcription of 
EIF4EBP1 (Azar et al., 2008), possibly via the 
transcription factor Egr-1 (Rolli-Derkinderen et al., 
2003). 
Pseudogene 
Two pseudogenes with homology to 4E-BP1 exist in 
the human genome, located at 14q11.2 (LOC768328) 
and 22q12 (EIF4EBP1P), with the latter pseudogene 
present on the antisense strand of the gene locus 




Human 4E-BP1 is a 118 amino acid protein (119 amino 
acids including the initiating methionine) and is 
encoded by an mRNA containing 877 nucleotides 
(including a short poly(A) tail).  
The mRNA has a 72 nucleotide 5' untranslated region 
and a 448 nucleotide 3' untranslated region. The coding 
region comprises nucleotides 73-429. The protein can 
be reversibly phosphorylated at Thr37, Thr46, Ser65, 
Thr70, Ser83, Ser101 and Ser112 in response to a variety of 
physiological stimuli. The key enzyme involved in 
these phosphorylations is the protein kinase mTOR, but 
other kinases may also be involved (Yonezawa et al., 
2004). 
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The diagram illustrates key regulatory features of the human 4E-BP1 protein, including the RAIP and TOS motifs that are important for 
the phosphorylation of the protein at Thr37, Thr46, Ser65, Thr70 and Ser101 by the Raptor/mTOR complex (Eguchi et al., 2006; Lee et al., 
2008). Additional phosphorylation sites have been identified at Ser83 and Ser112. The region required for binding of 4E-BP1 to initiation 
factor eIF4E and a site of cleavage of the protein by caspases in apoptotic cells are also shown (diagram adapted from an original 
prepared by Dr C. Constantinou). 
 
Expression 
4E-BP1 is ubiquitously expressed, although its 
presence is not essential to the viability of cells or the 
organism as a whole (Le Bacquer et al., 2007). The 
protein is stable (half-life more than 16h) but can be 
ubiquitinated and targeted for degradation by a 
mechanism that responds to its state of phosphorylation 
(Elia et al., 2008).  
The level of expression and state of phosphorylation of 
the protein may influence cellular phenotype, with high 
levels of phosphorylated 4E-BP1 in breast, ovary, and
prostate tumours being associated with malignant 
progression and an adverse prognosis (Armengol et al., 
2007).  
Conversely, hypophosphorylated 4E-BP1 may have an 
anti-oncogenic role due to its inhibitory effect on eIF4E 
and its potential pro-apoptotic properties (Li et al., 
2002). 
Localisation 
4E-BP1 is present in both cytoplasm and nucleus. The 
hypophosphorylated protein in the latter compartment 
can sequester eIF4E within the nucleus under 
conditions of physiological stress (Rong et al., 2008). 
Function 
The members of the 4E-BP family of proteins act by 
binding to the mRNA cap-binding protein eukaryotic 
initiation factor 4E (eIF4E), in competition with 
another initiation factor, eIF4G, that is essential for 
polypeptide chain initiation. Thus the availability of 
eIF4E for translation of cap-dependent mRNAs is 
limited by the extent to which this factor is sequestered 
by the 4E-BPs. 
4E-BP1 is reversibly phosphorylated at multiple sites 
(see diagram above), in response to several 
physiological signals that promote translation (Proud, 
2004; Wang et al., 2005; Proud, 2006). Such 
phosphorylations lower the affinity of 4E-BP1 for 
eIF4E and result in the dissociation of the two proteins, 
thereby enhancing the level of active eIF4E and 
promoting the translation of capped mRNAs, most 
likely in a selective manner (Averous et al., 2008). 
Conversely, physiological stresses and other conditi s 
that inhibit translation - e.g. exposure of cells to 
cytokines of the TNFalpha family (Lang et al., 2007; 
Jeffrey et al., 2006) or activation of the tumour 
suppressor protein p53 (Tilleray et al., 2006; 
Constantinou and Clemens, 2007) - cause 
dephosphorylation of 4E-BP1 and increase binding of 
the latter to eIF4E. 4E-BP1 is also susceptible to other 
post-translational modifications, notably specific 
proteolytic cleavages (Tee and Proud, 2002; 
Constantinou et al., 2008) and phosphorylation-
dependent ubiquitination (Elia et al., 2008). 
There is good evidence for involvement of 4E-BP1 in 
malignant transformation. The protein can negatively 
regulate cell growth, block cell cycle progression and 
revert the transformed phenotype of cells over-
expressing eIF4E (Rousseau et al., 1996; Jiang et al., 
2003; Barnhart et al., 2008). It has been shown that 4E-
BP1 is a key regulator of the oncogenic Akt (protein 
kinase B) and ERK (extracellular-regulated kinase) 
signalling pathways and it integrates the function of 
these pathways in tumours (She et al., 2010). 
Consistent with this, high levels of phosphorylated 
(inactive) 4E-BP1 indicate poor prognosis in some 
cancer patients (Castellvi et al., 2006; Frederick et al., 
2011). 
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CLUSTAL 2.0.10 multiple sequence alignment. 
 
Although 4E-BP1 is not essential to viability the 
protein (together with its homologue 4E-BP2) is 
important for regulation of adipogenesis and insulin 
resistance (Le Bacquer et al., 2007). The 4E-BPs have
also been reported to play a role in myelopoiesis (Ol on 
et al., 2009). There is a major role for 4E-BP1 in the
responses of cells to hypoxia, which promotes 
dephosphorylation of the protein (Koritzinsky et al., 
2006; Connolly et al., 2006 ; Barnhart et al., 2008). It is 
likely that this response implements hypoxia-induced 
changes in gene expression at the translational level 
(Magagnin et al., 2008; Barnhart et al., 2008). 
Homology 
4E-BP1 was identified alongside another member of 
the eIF4E-binding protein family designated 4E-BP2 
(Pause et al., 1994). A further homologue has also been 
identified, 4E-BP3 (Poulin et al., 1998), and these 
proteins respectively share 55,7% identity (82,0% 
similarity) and 50,8% identity (66,9% similarity) with 
4E-BP1. All share the central eIF4E binding motif and 
are capable of competing with the eIF4G proteins for 
binding to eIF4E. 
Mutations 
Note 




Elevated expression of eIF4E in human cancer often 
correlates with poor prognosis (Culjkovic et al., 2007). 
Likewise, expression of phosphorylated 4E-BP1 (which 
is inactive as an inhibitor of eIF4E) is associated with 
malignant progression and an adverse prognosis in 
breast, ovary, and prostate tumours (Armengol et al., 
2007). 
Oncogenesis 
Because 4E-BP1 is an antagonist of the oncogenic 
initiation factor eIF4E (Avdulov et al., 2004), it might 
be anticipated that 4E-BP1 could function as a pro-
apoptotic tumour suppressor protein. However it has
been reported that a majority of large advanced breast 
cancers overexpress 4E-BP1 (Braunstein et al., 2007). 
The latter may contribute to tumourigenesis (in 
combination with overexpressed eIF4G) by promoting 
a hypoxia-activated switch in selective mRNA 
translation that enhances angiogenesis and tumour cell 
growth and survival. 
Breakpoints 
Note 
Although no breakpoints within the 4E-BP1 gene locus 
have been identified, the chromosomal region 
containing 4E-BP1 (8p11-12) is frequently rearranged 
in breast carcinomas. However, microarray profiling of 
the genes within these regions in breast tumours and 
cell lines shows that rearrangements of the 
chromosome do not correlate with significantly 
changed 4E-BP1 mRNA expression (Gelsi-Boyer et al., 
2005). 
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